Pulmonary Fibrosis

A deep learning generative model is capable of autonomously learning about idiopathic pulmonary fibrosis.

The genes are all associated with cellular senescence, which is believed to play an important role in the development of idiopathic pulmonary fibrosis (IPF).

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City, reflects on how the reality of COVID-19 infection proved far more complex than initially thought.

The potential therapy for idiopathic pulmonary fibrosis is notable because not only was the small molecule discovered by artificial intelligence, but the drug’s target itself was, too.

While citing overwhelming barriers patients in rural areas face when accessing care, providers noted the potential of telehealth to improve access in a survey.

Patients reported that side effects often impacted their quality of life (QOL). However, most patients said their treatment helped slow disease progression and gave them hope.

Even a 2% decline in lung function predicted poor outcomes for patients with idiopathic pulmonary fibrosis (IPF) in a new study.

Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.

Researchers are working to redefine diagnosis and treatment with data-driven tools aimed at identifying patients earlier and guiding precision care.

The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary hypertension.

Clinical trials for idiopathic pulmonary fibrosis could benefit from improved patient engagement to include diverse perspectives and inclusive practices.

Forced oscillation technique (FOT) can enhance early detection and management of progressive pulmonary fibrosis.

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.

The top 5 idiopathic pulmonary fibrosis (IPF) articles of 2024 explored topics like the effect of oxygen therapy on health care costs and mortality; delayed diagnoses leading to worse outcomes; new drug trials; the impact of diabetes on pulmonary health; and the growing body of research on macrophages and pulmonary fibrosis.

Patients with interstitial lung disease (ILD) experience significantly higher rates of fatigue and excessive daytime sleepiness than healthy individuals.

A trio of experts discuss the importance of early diagnosis, treatment barriers, and therapies in the pipeline for idiopathic pulmonary fibrosis (IPF).

Top coverage from the European Respiratory Society (ERS) Congress 2024 spanned various topics, including artificial intelligence–powered robots transforming respiratory care and late-breaking findings on an epilepsy drug showing promise for treating obstructive sleep apnea.

In part 2 of our interview, Cesar Davila-Chapa, MD, discusses key findings, limitations, and future research directions from his study on racial disparities in idiopathic pulmonary fibrosis (IPF) outcomes.

COVID-19 vaccination significantly reduced anxiety and depression in patients with idiopathic pulmonary fibrosis (IPF), improving their mental health one month after the first dose.

A study in Japan found that antifibrotic treatment rates for patients with idiopathic pulmonary fibrosis (IPF) varied by medical facility, with higher treatment rates observed in referral hospitals than in general hospitals or clinics.

The increase in the global burden of interstitial lung disease (ILD) and pulmonary sarcoidosis had the greatest impact on countries with a high sociodemographic index.

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options for patients with idiopathic pulmonary fibrosis (IPF).